KSC:005690

Pharmicell Co., Ltd. · KSC · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 12:42 UTC

Last close

n/aKRW

Market data

11.8xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
35.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
29.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.12Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

Five bars, one line

lens 7 of 9

2.64x

-14.46x

24.49x

3.29x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales2.64x
Its own average over 10 years, 43.21B.
Profit-14.46x
Its own average over 10 years, -2.79B.
Free cash flow24.49x
Its own average over 10 years, 1.37B.
Debt3.29x
Its own average over 9 years, 4.43B.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 24.49 times.

Sales is 2.64 times its own 10-year average; Profit is -14.46 times its own 10-year average; Free cash flow is 24.49 times its own 10-year average; Debt is 3.29 times its own 9-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average2.64
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 10-year average-14.46
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 10-year average24.49
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 9-year average3.29
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW